Company Filing History:
Years Active: 2007-2010
Title: Innovator Spotlight: Mioko Harada
Introduction
Mioko Harada is a notable inventor based in Tsukuba, Japan, recognized for her contributions to pharmaceutical innovations. She holds three patents that focus on advancing treatments for obesity and appetite regulation, showcasing her commitment to enhancing human health through science and technology.
Latest Patents
One of Harada's significant inventions is a ligand to GPR8. This invention provides specific polypeptides capable of binding to GPR8 and its derivatives, including amides or esters. The significance of this ligand lies in its utility for developing receptor-binding assay systems using a GPR8 expression system, facilitating the screening of candidate compounds that could lead to preventive or therapeutic agents for obesity, appetite stimulants, and prolactin production inhibitors.
Another crucial patent involves a method for screening MCH receptor antagonists and agonists. This screening method identifies compounds that affect the binding properties of MCH to its receptors, facilitating the discovery of SLT agonists that can promote appetite and SLT antagonists as potential therapeutic agents for obesity.
Career Highlights
Harada is currently associated with Takeda Pharmaceutical Company Limited, where her work focuses on innovation in pharmaceuticals. Throughout her career, she has demonstrated a remarkable ability to translate scientific discoveries into practical applications that address crucial health issues.
Collaborations
In her research endeavors, Mioko collaborates with notable colleagues such as Masaaki Mori and Yukio Shimomura. Together, they contribute to the ongoing efforts in the pharmaceutical field, aiming to enhance the quality of life through innovative drug development.
Conclusion
Mioko Harada's influential work in the realm of pharmaceuticals, marked by her patents and collaborations, reflects her dedication to innovation in health sciences. Her research has the potential to impact treatments for obesity and appetite control significantly. As she continues her work at Takeda Pharmaceutical Company Limited, the scientific community eagerly anticipates her future contributions to the field.